NLRP3 and cancer: In addition, selective estrogen receptorα antagonists promote β-catenin degradation via inhibition of NLRP3. Collectively, these results indicate that NLRs are potential cancer markers that mediate estrogen receptor/Wnt/β-catenin signaling axis (61) (Table 2).